Elevated serum anti‐Saccharomyces cerevisiae antibody accompanied by gut mycobiota dysbiosis as a biomarker of diagnosis in patients with de novo Parkinson disease

• DOI: 10.1111/ene.15711
• Publication Date: 2023-01-25T05:33:09Z
• Authors: Ying Chen; Li‐Ying Zhang; Yi Fang; Chuan Li; Dan‐Dan Xia; Gong Zhang; Yi Wen; Song‐Zhao Zhang; Liu Hu; Lu‐Yan Gu; Yi Liu; Jun Tian; Ya‐Ping Yan; Xin‐Zhen Yin; Zhi‐Hua Tao; Bao‐Rong Zhang; Jia‐Li Pu
• Keywords: Mycobiota; Dysbiosis

Abstract Background and purpose Intestinal inflammation gut microbiota dysbiosis contribute to Parkinson disease (PD) pathogenesis, growing evidence suggests associations between inflammatory bowel diseases (IBD) PD. Considered as markers of chronic gastrointestinal inflammation, elevated serum anti‐ Saccharomyces cerevisiae antibody (ASCA) levels, against certain fungal components, are related IBD, but their effect on PD is yet be investigated. Methods Serum ASCA IgG IgA levels were measured using an enzyme‐linked immunosorbent assay, the mycobiota communities investigated ITS2 sequencing analyzed Qiime pipeline. Results The study included 393 subjects (148 healthy controls [HCs], 140 with PD, 105 essential tremor [ET]). Both significantly higher in group than ET HC groups. Combining occurrence constipation could discriminate patients from (area under curve [AUC] = 0.81, 95% confidence interval [CI] 0.76–0.86) (AUC 0.85, CI 0.79–0.89). Furthermore, composition community differed relative abundances , Aspergillus Candida solani flavus ASV601_Fungi, ASV866_Fungi, ASV755_Fungi group, enriched Malassezia restricta was found group. Conclusions Our identified de novo